Analysis of "Dose Accuracy and Reliability of a Connected Insulin Pen System".

J Diabetes Sci Technol

Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine, New York, NY, USA.

Published: January 2025

In an article in the , Backfish and coauthors examined the dose accuracy and reliability of the Tempo Pen and Tempo Smart Button connected insulin pen system. This study sponsored by Eli Lilly and Company found that this system met the International Organization for Standardization 11608-1:2014 requirements for dose accuracy at a range of doses, as well as the data transfer requirements after all injections. While these results are very encouraging, they were based on simulated human factors data while data from a human factors validation study where individuals successfully dialed and administered correct doses was not reported. There is a need for further studies in a variety of populations that would greatly benefit from this enhanced insulin pen technology to facilitate optimization of dose adjustments based on accurate and reliable insulin dosing data.

Download full-text PDF

Source
http://dx.doi.org/10.1177/19322968251314522DOI Listing

Publication Analysis

Top Keywords

insulin pen
12
accuracy reliability
8
connected insulin
8
dose accuracy
8
human factors
8
analysis "dose
4
"dose accuracy
4
reliability connected
4
insulin
4
pen
4

Similar Publications

Analysis of "Dose Accuracy and Reliability of a Connected Insulin Pen System".

J Diabetes Sci Technol

January 2025

Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine, New York, NY, USA.

In an article in the , Backfish and coauthors examined the dose accuracy and reliability of the Tempo Pen and Tempo Smart Button connected insulin pen system. This study sponsored by Eli Lilly and Company found that this system met the International Organization for Standardization 11608-1:2014 requirements for dose accuracy at a range of doses, as well as the data transfer requirements after all injections. While these results are very encouraging, they were based on simulated human factors data while data from a human factors validation study where individuals successfully dialed and administered correct doses was not reported.

View Article and Find Full Text PDF

Level of Satisfaction Among Patients Using Insulin Administered by Pen vs Vial/Syringe. An Observational Prospective Study.

Patient Prefer Adherence

January 2025

Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S.A, Pereira, Risaralda, Colombia.

Purpose: To determine the satisfaction of patients with diabetes mellitus who used subcutaneous insulin application devices in Colombia.

Patients And Methods: An observational prospective study of patients with diabetes mellitus receiving insulin treatment in Colombia. Sociodemographic, comorbidity and pharmacological data were taken from a drug dispensing database.

View Article and Find Full Text PDF

Smart Insulin Pen in Pregnant Women with Type 1 Diabetes: An Encouraging Case Series.

Healthcare (Basel)

December 2024

Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

The management of type 1 diabetes in pregnancy with new technologies is challenging. Sometimes the complexity of new-generation systems such as "continuous subcutaneous insulin infusion, CSII" and patient or provider preference do not allow their use, so women with type 1 diabetes in pregnancy continue to be treated with subcutaneous multiple-injection insulin therapy using pens. Smart insulin pens are new tools that allow for data collection on insulin dose and time of administration and have additional connectivity features.

View Article and Find Full Text PDF

Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls.

Calcif Tissue Int

January 2025

Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Aeschenvorstadt 57, 4051, Basel, Switzerland.

Pentosidine (PEN), a surrogate marker of advanced glycation end-product formation, reflects increased non-enzymatic cross-linking in bone collagen, which is thought to be an important determinant of bone fragility in type 2 diabetes mellitus (T2DM). We aimed to investigate serum concentrations of PEN in patients with T2DM and controls without T2DM and to examine its relationship with bone parameters and metabolic state such as glycaemic control, insulin resistance and body weight. In a cross-sectional study-design, data from postmenopausal women and men with T2DM (n = 110) and controls without T2DM (n = 111) were evaluated.

View Article and Find Full Text PDF

This case report presents a rare instance of a 28-year-old female patient with insulin-induced abdominal lipodystrophy, who presented to the emergency department with symptoms of an anxiety attack triggered by body image distress. She was diagnosed with type 1 diabetes at the age of eight years. For the past 10 years, she has been using insulin glargine and insulin lispro, injecting roughly five times per day.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!